# Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

> **NCT05328726** · PHASE1 · COMPLETED · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GZR-18
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05328726
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-08
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-03-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328726, "Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05328726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*